HD-OPM Archive
Topics › Inflammation & CRP

Statins, bempedoic acid, fibrates and ezetimibe lower hsCRP; PCSK9 inhibitors do not

Louis Nervegna · Jun 12, 2026 · ♥ 21 reactions · 9 comments · original Facebook post
Inflammation & CRPStatinsPCSK9, ezetimibe & newer drugs
↻ This is a repost. The main version (highest ranked) is Statins, bempedoic acid, ezetimibe, fibrates and PCSK9 inhibitors all lower hsCRP · Dec 28, 2025.
AI summary & key facts

Louis summarizes a meta-analysis of randomized trials of lipid-lowering therapies and CRP. Statins, bempedoic acid, ezetimibe, fibrates and omega-3 all reduced hsCRP, whereas PCSK9 inhibitors seemed to raise it modestly. He suggests high LDL is itself inflammatory when it oxidizes in the arterial wall.

Statins, bempedoic acid, ezetimibe, and fibrates, all lower inflammation and hsCRP.

Multiple trials have proven this.

Here are the average amounts by which they lower hsCRP:

Statins - 17.3%
Bempedoic acid - 20%
Ezetimibe - 3.2%
Fibrates - 10.3%

(For comparison, fish oil lowers hsCRP by about 12.8%.)

Part of the reason why they all do this is because high LDL itself can be inflammatory. When LDL gets inside the arterial wall and oxidizes, it attracts immune cells which generate inflammation. This raises levels of hsCRP and other inflammatory markers.

The only major exception is PCSK9 inhibitors, which actually seem to modestly increase hsCRP.

#crpHD #hscrpHD #inflammationHD #statinsinflammationHD #statinsHD #bempedoicacidHD #ezetimibeHD #fishoilHD #omega3HD #fibratesHD #pcsk9HD

Research cited

Shared from Gokhan Can · original post

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

"Statins, bempedoic acid, ezetimibe, and omega-3 FAs significantly reduce serum CRP concentration, independently of LDL-C reductions."

Paper · Cardiovasc Res · 2024Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials.Chronic low-degree inflammation is a hallmark of atherosclerotic cardiovascular (CV) disease. To assess the effect of lipid-lowering therapies on C-reactive protein (CRP), a biomarker of inflammation, we conducted a meta-analysis according to the PRISMA guidelines. Databases were searched from inception to July 2023. Inclusion criteria were: (i) randomized controlled trials (RCTs) in human, Phase II, III, or IV;…academic.oup.com

PS: Also consider Colchicine, GLP1-RA, low dose pioglitazone, curcumin, 4 herb synergy, milk thistle...

No photo description available.
← newer: Pro soccer players average ~160 mg/dL glucose during matchesolder: Statins cut hsCRP about 1 mg/L and CRP 3 mg/L in CVD, 26-RCT →